Stocks of Adma Biologics Inc (NASDAQ:ADMA) traded higher last session on Wall Street, down -3.66% to $20.81.
ADMA stock price is now -0.08% away from the 50-day moving average and 10.69% away from the 200-day moving average. The market capitalization of the company currently stands at $4.97B.
On October 13, 2022, Mizuho recently initiated its ‘Buy’ rating on the stock quoting a target price of $5, while ‘Raymond James’ rates the stock as ‘Strong Buy’
In other news, ELMS STEVE, Director bought 425,621 shares of the company’s stock on Jun 12 ’25. The stock was bought for $9,308,331 at an average price of $21.87. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 09 ’25, Director Guiheen Lawrence P. sold 20,000 shares of the business’s stock. A total of $419,200 was realized by selling the stock at an average price of $20.96. This leaves the insider owning 94,830 shares of the company worth $1.97 million. A total of 3.49% of the company’s stock is owned by insiders.
During the past 12 months, Adma Biologics Inc has had a low of $10.21 and a high of $25.67. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 6.58, and a quick ratio of 3.36. According to the stock market information, the enterprise value for the company is $4978447872, which is based on a 24.65 price-to-earnings ratio, a 0.61 price-to-earnings-growth ratio, and a beta of 0.48. The fifty day moving average price for ADMA is $20.8276 and a two-hundred day moving average price translates $18.8009 for the stock.
The latest earnings results from Adma Biologics Inc (NASDAQ: ADMA) was released for 2025-03-31. The net profit margin was 45.01% and return on equity was 78.45% for ADMA. The company reported revenue of $114.8 million for the quarter, compared to $81.88 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 40.22 percent. For the current quarter, analysts expect ADMA to generate $124.25M in revenue.
